Overview
- 4 inspections across 4 sites are on record.
- 13 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2022-02-25.
At a glance
Inspections
4
Sites
4
Observations
13
Career since
Aug 2021
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| MOHNARK PHARMACEUTICALS INC. | 25 Feb 2022 | Human Drugs | View 483 → |
| Noven Pharmaceuticals, Inc. | 17 Nov 2021 | Human Drugs | View 483 → |
| Lonza Tampa LLC | 1 Oct 2021 | Human Drugs | View 483 → |
| CoreRX Inc. | 13 Aug 2021 | Human Drugs |
Sites inspected
MOHNARK PHARMACEUTICALS INC.Davie, United States1 insp.
Noven Pharmaceuticals, Inc.Miami, United States1 insp.
Lonza Tampa LLCTampa, United States1 insp.
CoreRX Inc.Clearwater, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Full investigator report
Get the verbatim findings behind Lillian M Colon-Mcknight's 13 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site